Mastering Immunotherapy-Based Approaches in Advanced Endometrial Cancer: A Pharmacist’s Perspective

A PTCE virtual symposium affiliated with the 2024 HOPA Annual Conference

Program Description

It is important for pharmacists to be aware of the implications of recent guideline updates and have a knowledge of emerging data for advanced endometrial cancer. As treatment options multiply, fostering informed discussions with patients and individualizing treatment plans is paramount. In addition, current treatment offers improved survival but does not come without concerns related to potential adverse effects. Pharmacists have a pivotal role in preventing, monitoring, and treating adverse effects, and they can provide support to patients throughout their treatment journey. This activity will include a panel discussion spotlighting challenging cases. Faculty will provide their insight and experience in the intricate decision-making processes in the treatment of advanced endometrial cancer and the adept management of toxicities.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: June 4, 2024
Expiration date: June 4, 2025

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the molecular mechanisms underpinning endometrial cancer, particularly in the context of personalized medicine, to facilitate the informed and optimized use of immune checkpoint inhibitors in its treatment
• Translate updated clinical evidence and emerging trends in primary advanced or recurrent endometrial cancer into actionable insights for patient care
• Identify appropriate interventions that mitigate the severity of toxicities caused by either immunotherapy or targeted therapy for advanced endometrial cancer treatment

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-174-H01-P. The activity is available for CE credit through June 4, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Amy Ly Indorf, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Jennifer MacDonald, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Speakers Bureau: GlaxoSmithKline

Sarah Hayward, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:

Consultant (advisory board): Merck, Immunogen, Seagen/Genmab, Verastem

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms